Introduction
Adaptive designs of clinical trials facilitate mid-trial modifications based on interim information from internal or external sources. Recently, methods have been proposed to facilitate adaptivity for prospective modification of many trial features, including randomization [1, 2] . Friedman et al. [3] broadly refer to randomization methods that facilitate mid-trial adjustments to the allocation ratios as adaptive. Two types of adaptive randomization (AR) procedures are commonly implemented in clinical trials. Baseline AR designs are used to balance the study arms with respect to prognostic factors that are available at baseline [4, 5] . By contrast, response-adaptive or outcome-adaptive designs were developed for the purpose of assigning more patients to more effective or safer treatment regimens based on interim data from an ongoing trial [6] [7] [8] [9] [10] . While Korn and Freidlin [11] have questioned the usefulness of designs that use outcome-adaptive randomization for this purpose in the two-armed setting, the potential remains to benefit from adaptive designs that assign more new patients to learn about newer, less studied therapies in the presence of historical controls that satisfy Pocock's [12] six 'acceptability' criteria (p. 177). Such designs promise to enhance efficiency when implementing controlled clinical trials that follow recent evaluations of a control therapy by facilitating more precise estimates of the treatment effect. However, assumptions of exchangeability among the historical and concurrent control data may lead to poor frequentist operating characteristics and highly biased results.
In this article, we propose an adaptive analog of an actual randomized controlled colorectal cancer trial originally reported by Goldberg et al. [13] that succeeded a similar trial reported by Saltz et al. [14] . The Goldberg trial used as its control arm an identical treatment to that found superior in the Saltz trial. The proposed adaptive design is based on a randomization method that adapts as a function of the relative informativeness of the historical data for evaluating the endpoint of interest (in this case, time to disease progression (TTP)). Actual patientlevel data from the Saltz trial (historical) and enrollment dates from the Goldberg trial (current) are used to simulate the proposed adaptive design's frequentist properties. Historical data are formally incorporated into the Bayesian analysis of the Goldberg trial using commensurate priors [15, 16] in the context of a piecewise exponential model [17] .
In the absence of strong evidence for heterogeneity among the historical and accumulating current controls, the proposed adaptive design assigns more new patients to learn more about novel therapies, thus attempting to impose balance between concurrent and historical information. After an initial stage of equal allocation, the allocation probability is adjusted as a function of the effective historical sample size (EHSS). EHSS is defined as a function of a measure of the degree to which estimates of model parameters are 'shrunk' toward their historical counterparts.
Designs such as this promise to be important in contexts where reliance on preexisting information is unavoidable, as occurs when the control therapy is exceptionally hazardous or expensive, or when the disease is rare. There are many subareas of oncology that could benefit from applications of these methodologies, including rare subtypes of sarcomas; rare progressions of renal cell carcinoma, such as advanced sarcomatoid; and pediatric brain tumors, such as choroid plexus carcinoma, medulloblastoma, and pontine glioma, to mention a few.
This article proceeds as follows. Section 'Colon cancer trials' describes the colorectal cancer clinical trials that motivated the research. Section 'Effective historical sample size' introduces the concept of EHSS in the context of Bayesian analysis. Section 'Probability models' introduces the probability models used to evaluate TTP in the proposed, adaptive trial. In section 'Adaptive trial design', we formulate our proposed alternative, adaptive design. Section 'Simulations' discusses the adaptive design's frequentist properties. Finally, section 'Discussion' concludes and suggests avenues for further development.
Colon cancer trials
The proposed adaptive design is motivated by two successive randomized controlled colorectal cancer clinical trials originally reported in studies of Goldberg et al. [13] and Saltz et al. [14] . The initial trial [14] randomized 683 patients with previously untreated metastatic colorectal cancer between May 1996 and May 1998 to one of three regimens: irinotecan alone, irinotecan and bolus fluorouracil plus leucovorin (IFL), or a regimen of 5-fluorouracil and leucovorin (5FU/LV) ('standard therapy'). IFL resulted in significantly longer TTP and overall survival than both irinotecan alone and 5FU/LV, and thus became the standard of care therapy. The subsequent trial [13] compared two new (at the time) drug combinations in 795 patients with previously untreated metastatic colorectal cancer, randomized between May 1999 and April 2001. Patients in the first drug group received the current 'standard therapy', the IFL regimen identical to that used in the historical study. The second group received oxaliplatin and infused fluorouracil plus leucovorin (abbreviated as FOLFOX), while the third group received irinotecan and oxaliplatin (abbreviated as IROX); both of the latter two regimens were new as of the beginning of the second trial.
Historical control data from the Saltz trial appear to satisfy Pocock's [12] acceptability criteria. Less than 1 year elapsed in the time between the last patient enrolling into the Saltz trial and the first patient enrolling into the Goldberg trial. Both trials used identically defined IFL therapies, both trials used similar inclusion and exclusion criteria, and both used identical criteria to assess TTP. For example, inclusion required an Eastern Cooperative Oncology Group performance status (PS) of 2 or less. Exploratory data analysis suggests that the trials enrolled patients from comparable populations. The first, second, and third quartiles of the sum of the longest diameters (in cm) of up to nine tumors at baseline are 5.0, 8.5, and 12.8 in the Saltz trial and 4.7, 7.9, and 12.7 in the Goldberg trial; for age (in years), they are 54, 62, and 69 in the Saltz trial and 53, 61, and 69 in the Goldberg trial.
Our proposed adaptive trial compares TTP between the FOLFOX and IFL regimens. The historical controls consist of patients randomized to IFL in the Saltz study; the current data consist of patients randomized to IFL or FOLFOX in the Goldberg trial. For simplicity, we omit data from the irinotecan alone and 5FU/LV arms in the Saltz study, and the IROX arm in the Goldberg study. We consider only patients who had measurable tumors at baseline, bringing the total sample size to 643: 224 historical and 419 current observations. Among the current patients, there are 208 controls (IFL), and 211 patients are treated with the new regimen (FOLFOX).
Effective historical sample size
Balancing information among treatment arms, as data accrue in an adaptive, controlled trial, requires interim assessment of the relative informativeness of the historical data. Before formulating our adaptive trial design, we briefly introduce the concept of EHSS in the context of Bayesian analysis, a concept that will be used in section 'Adaptive trial design' to adjust allocation probabilities among study arms for new patients enrolled thereafter, in the context of a hierarchical model. The concept of EHSS is related to the work of Morita et al. [18] , who considered effective sample sizes of parametric prior distributions for nonhierarchical models.
Let y 0 denote the vector of outcomes for n 0 patients assigned to the control therapy in the historical trial. Similarly, let y denote the vector of outcomes for n patients in the current trial. Let u 0 and u denote analogous model parameters and L ujy ð Þ and L 0 u 0 jy 0 À Á denote the likelihood functions corresponding to the historical and current data, respectively, where u is the parameter of interest. Let p Ã (u) denote a suitable noninformative prior distribution for u. If the historical information is ignored, inference proceeds with respect to the posterior distribution of ujy
We refer to (1) as the 'reference' model. Now consider borrowing strength from the historical data. We may model a conditional relationship between u and u 0 by assuming a conditional prior distribution, p(uju 0 , h), that is dependent upon a hyperparameter, h, controlling the amount of crossstudy borrowing. Let p Ã 0 (u 0 ) denote a noninformative prior distribution for u 0 . Inference proceeds with respect to the posterior distribution of ujy 0 , y, h induced by the Bayesian model
Model (2) facilitates borrowing of strength via joint modeling of the historical and current data. Thus, we refer to model (2) as the 'joint' model. Let P Ã y ð Þ denote the posterior precision of ujy corresponding to inference under the reference
denote the posterior precision of ujy 0 , y, h corresponding to inference under the joint model, P y 0 , y, h À Á = ½E ujy 0 , y, h fu À E ujy 0 , y, h (u)g 2 À1 . If the relationship among sample size and precision is reasonably linear under the reference model, then the rate of precision per patient may be approximated by P Ã y ð Þ=n. Therefore, the effective sample size of the joint model's posterior is approximately n P y 0 , y, h À Á P Ã y ð Þ À Á , suggesting that a sensible functional relationship between joint posterior precision and EHSS follows as given
In this formulation, EHSS is approximately the effective sample size of the joint posterior minus the current sample size n. If the joint model leads to little gain in precision, then the EHSS is small. In contrast, relatively large gains in precision will produce large values of EHSS. Of note, the above formulation considers the case where u is a scalar. Mapping relative gains in precision among multiple parameters into a single EHSS presents additional complexity. Our example adaptive colon cancer trial presents one approach for time-to-event analysis using a piecewise exponential likelihood with multiple baseline hazards.
Probability models
Pocock [12] proposed Bayesian models for borrowing of strength from historical controls for time-toevent data in the context of parametric exponential models. He suggested that inference should proceed with fixed 'magnitudes' of the historical bias, noting that one may wish to repeat the analysis with several alternative values expressing varying degrees of trust in the historical controls. For the case of one historical study, the general commensurate prior approach [15] extends the approach of Pocock and proposes a set of prior distributions for estimating the magnitude of historical bias from the observed data in the context of fully hierarchical and empirical Bayesian analysis for parametric inference with exponential families.
Piecewise exponential likelihood
Let Y and c denote vectors containing time-to-event variables and right-censoring indicators for n patients, respectively. We use a piecewise exponential model that assumes constant baseline hazards within finite partitions of the time axis. Such a flexible model accommodates numerous shapes of the baseline hazard over the partition intervals. Following the notation of Ibrahim et al. [17] (p. 48), we partition the time axis into J + 1 intervals,
, and s J denote the end of patient follow-up, the maximum possible time that a patient could be followed during the trial. For y in the jth interval, s jÀ1 \y s j , the model assumes a constant baseline hazard l j . 0, j= 1, ...,J. Suppose x i is a vector of p patient-specific baseline covariates, where i = 1, ..., n indexes patient, and b=(b 1 , ..., b p ) is the corresponding vector of regression coefficients. Let l denote the vector of baseline hazards, l =(l 1 , ...,l J ). Within the jth time partition interval, the hazard for the ith patient is assumed to be h(l j ,
Let u denote the vector of model parameters u =(l,b). The ith patient's full contribution to the likelihood is as follows
The likelihood in (4) assumes that the ratio of hazards for two individuals is constant over time, and thus represents a proportional hazards model.
Commensurate prior model
In this subsection, we formulate a commensurate prior model [15] for the scenario presented by the motivating successive colon cancer trials, where historical data are available only for the control group. The general commensurate prior approach facilitates estimation of the extent to which analogous parameters from distinct data sources have similar ('commensurate') posteriors through the specification of a particular hierarchical model. Commensurate prior distributions center model parameters defined in the context of the likelihood for the current data at their historical counterparts. Hobbs et al. [15] use sparsityinducing spike-and-slab hyperpriors for the precision parameters to favor the concurrent information in the presence of heterogeneity. Let Y 0 and c 0 denote vectors of length n 0 containing time-to-event variables and right-censoring indicators for patients assigned to the current control therapy in the historical study. Let Y and c denote data from n patients in the current trial. Furthermore, let d i denote an indicator of the novel treatment for the ith patient in the current trial, i = 1, . . . , n. In this context, the hazard for a historical patient in the jth time partition interval is identical to the jth historical baseline hazard, h(l 0, j ) = l 0, j . For the ith patient in the current trial, the jth baseline hazard, l j , is modified by novel treatment status,
where j is the log acceleration factor corresponding to the novel treatment. Both historical and current baseline hazard parameters are defined with respect to a single partition of the time axis characterized by boundary points 0\s 1 \s 2 \ . . . \s J \'.
To borrow strength from the historical controls, the commensurate prior approach can be applied by assuming a normal prior for the jth log baseline hazard, log (l j ), centered at its historical counterpart, log (l 0, j ), with precision t j : log (l j ); N( log (l 0, j ), 1=t j ). Given no additional prior information about the historical baseline hazards or novel treatment effect, inference may proceed with noninformative Gaussian prior distributions for the log (l 0, j )s and j. Let D and D 0 denote the current and historical data: D = (Y, d, c) and D 0 = (Y 0 , c 0 ), respectively. Let u denote the parameter vector u = j, log (l 1 ), . . . , log (l J ) È É , let u 0 denote the parameter vector u 0 = log (l 0, 1 ), . . . , log (l 0, J ) È É , and let t denote vector t = (t 1 , . . . , t J ). Following from (4), the joint posterior distribution of ujt is proportional to
where L Y 0 (u 0 j Á ) denotes the likelihood function corresponding to the piecewise exponential model for the historical data. Following Hobbs et al. [15] , we assume 'spike-andslab' prior distributions [19] for the t j s. This sparsity-inducing prior distribution is locally uniform between two limits, 0 S l \S u except for a bit of probability mass concentrated at a point K . S u
The additional hyperparameter, p 0 , denotes the prior probability of the existence within the slab, that is, S l t j S u . Given S l and K, smaller values of S u impose more borrowing of strength from the historical information, requiring more evidence for heterogeneity to overcome the prior probability mass assigned to the spike, 1 À p 0 . The aforementioned authors [15] show that this prior, when properly calibrated, leads to desirable bias-variance trade-offs for estimating concurrent effects in the context of commensurate prior models for exponential families. The results of our simulation study discussed in section 'Simulations' illustrate the advantages of the spike-and-slab commensurate prior model in this context. Markov chain Monte Carlo (MCMC) methods can be used to sample from the joint posterior model (5) .
Adaptive trial design
In this section, we formulate our proposed alternative design of the Goldberg trial following completion of the Saltz trial, which uses permuted-block randomization in both nonadaptive and adaptive phases. During the initial, nonadaptive phase, new patients are allocated equally between the control (IFL) and novel (FOLFOX) treatments until a targeted number of events selected to ensure that sufficient information has accrued to assess heterogeneity among the concurrent and historical controls. Thereafter, the treatment allocation probability is adjusted as a function of the EHSS and the number of patients assigned to each regimen. We use the piecewise exponential commensurate prior model (5) to jointly model the concurrent and historical data at each interim analysis. Given large EHSS, the adaptive design will randomize more new patients to the newer, less studied therapy.
Historical data
We use likelihood inference based on (4) to select the time axis partition for the full Bayesian analysis of the historical control data alone. The Akaike information criterion (AIC) optimal partition contains two intervals with boundary point at s = 243 days.
Thus, the piecewise exponential model contains two parameters characterizing baseline hazards within intervals ½0, 243) and ½243, max (Y 0 ), respectively. Figure 1 contains the associated TTP curves. The dashed line represents the Kaplan-Meier curve, while dotted lines correspond to associated 95% logtransformed [20] (p. 105) pointwise confidence intervals. Results for the piecewise exponential analysis are plotted with a solid line. Posterior summaries corresponding to the Bayesian analysis are provided in Table 1 . The posterior mean of median survival is approximately 205 days.
New trial
The Goldberg trial actually enrolled a total of n = 419 patients with measurable tumors assigned to either Our proposed trial consists of two phases. During the first, nonadaptive phase, patients are randomized 1:1 to the treatment regimens until O 1 events are observed. In order to ensure periodic balance in the number of patients assigned to each regimen, permuted-block randomization [21] is used with blocks of size 2 patients. An initial interim analysis to assess historical and concurrent control heterogeneity and compute EHSS will occur at that time. An adaptive, permuted-block randomization procedure that is a function of EHSS will be used to assign new patients to treatment arms thereafter in blocks of size B patients. EHSS will be reassessed after every Bth enrollment. The final analysis, using the joint model, occurs 51 months after the trial's initiation.
O 1 needs to be large enough so that sufficient information to assess control heterogeneity has accrued, yet small enough to justify the adaptive treatment allocation. In practice, O 1 and B should be selected in the context of a comprehensive assessment of the trial's operating characteristics in the presence of the historical data and expected patient enrollment. Our simulation study, discussed in the section 'Simulations', considers frequentist properties of the adaptive design under three different values of O 1 .
Data structure
Let T = 1552 denote the time of the trial's final analysis in days. Let t denote 'trial time', 0\t\T, and let e i , 0\e i \706, represent the time at which the ith patient enrolls. Let Y i (t) denote the random variable containing the value of the ith patient's TTP process at time t. Note that Y i (t) is recorded from e i , so that 0\Y i (t)\T À e i .
Let 
Posterior inference
The piecewise exponential models used for analysis at time t contain two baseline hazard parameters, l 1 and l 2 , corresponding to intervals ½0, m(t)) and ½m(t), T, where m(t) denotes the median TTP among the concurrent events observed by time t. This balances the available concurrent information between the two partition intervals at each analysis. Following the notation of section 'Probability models', let j denote the FOLFOX effect, and let u and u 0 denote the current and historical parameter vectors, where u = j, log (l 1 ), log (l 2 ) f g , and u 0 = log (l 0, 1 ), f log (l 0, 2 )g.
The reference model (1) in this context consists of the Bayesian piecewise exponential model that estimates u in the absence of the historical controls. It assumes noninformative Gaussian prior distributions (with small precision w = 0:01) for the FOLFOX effect, j, and the log baseline hazards, log (l 1 ) and log (l 2 ). At trial time t, the posterior distribution of uj D(t) under the reference model follows from (4) as Adaptive randomization using historical controls 435
The joint model (2) consists of a commensurate prior model (5) that borrows strength from the historical control data for estimating u. Following from (4), (5) , and (6), the posterior distribution of uj D(t), D 0 under the joint model at trial time t is
where p t (u) denotes the spike-and-slab prior distribution in (6) evaluated at u.
Effective number of historical controls and adaptive randomization
We compute EHSS at interim analyses, with use thereafter to guide the randomization procedure. In Appendix A, we investigate the linear association between number of events and posterior precision for log (l 1 )j D(t) in the context of the reference model (7) in the presence of the historical data. EHSS in this context maps the joint model's (8) relative gain in precision for estimating the set of current model parameters, l, that assume commensurate prior distributions (defined conditionally upon analogous historical parameters) to a number of additional events effectively observed for control. The first interim assessment of EHSS will occur at the trial time t 1 at which at least O 1 events have been observed, t 1 = arg min t P n(t)
i . EHSS will then be reassessed after every B additional patients enroll. Thus, the hth reassessment of EHSS will occur at trial time, t h , where t h = arg min t n(t) = n(t hÀ1 ) + B f g , h = 2, 3, . . .. Let O h denote the number of events that have occurred by trial time t h , O h = P n(t h ) i = 1 1 À c i (t h ) f g . Following section 'EHSS', let P Ã j D(t h ) f gdenote the posterior precision of log (l j )j D(t h ) at the hth interim analysis under the reference model (7) . Similarly, let P j D(t h ), D 0 f g denote the posterior precision of log (l j )j D(t h ), D 0 at the hth interim analysis under the joint model (8) . Recall that we have defined the time axis partition for analysis at time t h such that approximately O h =2 of the observed events occur within each time axis interval. The EHSS at the hth interim analysis follows from (3) as the sum of parameter-specific EHSSs (each based upon O h =2 events) for the current baseline hazards
We introduced EHSS (3) in the context of a Bayesian analysis with fixed hyperparameter h: Because we now average over the uncertainty for estimating hyperparameter t j , sufficient heterogeneity may result in less precision for the joint posterior infer-
Thus, we define EHSS h to be nonnegative valued.
After the hth interim analysis, we seek to obtain balance between the number of patients assigned to each regimen at the end of the trial relative to EHSS h in the context of a permuted-block randomization procedure with blocks of size B: Let n FOX (t) and n IFL (t) denote the number of patients assigned to FOLFOX and IFL at trial time t, respectively. Let R(t) denote the number of remaining patients at trial time t, R(t) = n À n IFL (t) À n FOX (t). Following the hth interim analysis, approximately p h B of the next B patients to enroll into the trial will be randomly assigned to FOLFOX and (1 À p h )B assigned to IFL, where p h is defined to satisfy the following equation
Therefore, p h is
The design can accommodate alternative default allocation ratios (besides 1:1) through modification of (10) to reflect the desired sample size imbalance at the trial's completion.
Simulations
We use simulation to evaluate the frequentist properties of the proposed alternative, adaptive design of the Goldberg trial. The simulation uses the actual patient-level data from n 0 = 224 historical controls assigned to IFL in the Saltz trial. Patient accrual in the simulated trials follows the actual enrollment dates (shown in Figure 2 ) for n = 419 patients randomized to FOLFOX or IFL during the Goldberg trial. Following subsection 'New trial', each simulated trial proceeds as follows. Patients are randomized 1:1 to IFL and FOLFOX using permuted-block randomization with blocks of size 2 until O 1 total events are observed at time t 1 . Thereafter, the probability of assigning a new patient to FOLFOX (11) adjusts in blocks of size B = 30 as a function of EHSS and the number of patients already assigned to each treatment arm. The joint commensurate prior model (8) used to compute EHSS at each interim analysis assumed spike-and-slab priors (6) for t j , j = 1, 2, . . . with the following hyperparameters: S l = 0:1, S u = 2, K = 5000, and p 0 = 0:5. A final analysis occurs at time T, 51 months following initial enrollment using the joint commensurate prior model with S u = 5 and p 0 = 0:9. The approach provides for more borrowing of strength from the historical data for computing EHSS, while facilitating slightly less borrowing when estimating the FOLFOX treatment effect, j, at the final analysis.
Frequentist properties are considered under varying magnitudes of assumed historical bias. Let u = fj, log (l 1 ), log (l 2 )g denote a set of fixed parameters characterizing a true state of the current model, where the baseline hazards,l 1 andl 2 , are defined under ½0, 243) and ½243, T (the AIC-optimal time axis partition for inference on the historical data alone). TTP for current patients are generated fromũ by shifting the log baseline hazards, log (l), from their historical estimates in Table 1 by D100%, wherẽ l(D)=(expfÀ5:689(1 ÀD)g, expfÀ4:858(1 ÀD)g). The historical data are assumed to be unbiased for the case where D=0. Without loss of generality, we fix j=0. Figure 3 plots results for mean EHSS and mean proportion of patients (out of n = 419) assigned to FOLFOX as functions of trial time. Each column corresponds to a different value of D100%, indicating relative magnitudes of assumed historical bias. Each graph in the bottom row of plots shows results for designs that initiate adaptive randomization after Adaptive randomization using historical controls 437 O 1 = 60, 90 and 120 observed events. Results are shown in the top row of plots for O 1 = 60. The plots show that increasing (decreasing) the baseline hazards leads to designs for which the initial computation of EHSS (determined by O 1 ), and initiation of the AR procedure thereafter, occurs earlier (later), on average. The top row of graphs show us that the actual historical data are most commensurate, on average, with the concurrent data when D100% = 0% (no change) and 5% (5% increase). The joint model borrows more strength from the historical data for these two scenarios, which leads to larger initial EHSS, and increasing trends over time as more events facilitate larger relative gains in posterior precision. This induces monotonically increasing trends over time in the mean proportion of patients assigned to FOLFOX. Note that because increasing the baseline line hazards yields fewer right-censored observations, EHSS is ultimately slightly larger for D100% = 5% when compared to D100% = 0%. In addition, AR initiates earlier for D100% = 5%. Thus, slightly more patients, on average, are assigned to FOLFOX when D100% = 5%. In contrast, the graphs show smaller initial EHSS with decreasing trends over time for the scenarios where D100% = À 10%, À 5%, and 10%, leading to less allocation to FOLFOX, on average. For these three scenarios, we see that the trends over time in mean proportion of patients assigned to FOLFOX for the three choices of O 1 ultimately converge. This suggests that our adaptive design is robust among reasonable choices in the initial timing of the interim assessments of EHSS.
Because our simulation study uses the actual historical data (as opposed to generating data from a piecewise exponential model with parameters fixed at their estimates in Table 1 ), the results lack symmetry around the case where the historical data are assumed to be unbiased, D = 0. The actual historical information appears to be most commensurate with accumulating concurrent information when current data are generated from the piecewise exponential model with 0\D\0:05.
In addition, we evaluated the adaptive design's frequentist properties for point estimation of the FOL-FOX effect, j, using the posterior mean at the final analysis, E jjD(T), D 0 (j). Specifically, we simulated expected bias and risk under squared error loss (SEL) with respect to the conditional distribution of the data, D(T), given D and the actual historical data, D 0 :
Results for the adaptive designs are compared to a fixed 1:1 allocation design with analysis under the associated reference ('no borrowing') model and a 'pooled' model, which simply pools the historical and current controls and randomizes new patients to FOLFOX with probability 0.77, so that the final analysis has approximately 321 total patients (historical and current) assigned to each regimen. Figure 4 presents expected bias and risk under SEL for estimating j as functions of D100%. Each column corresponds to a different value of O 1 . A total of 1000 replicated trials were simulated for each of the seven scenarios corresponding to values of D100% ranging from 215% to 15%. Each approach leads to an admissible estimator. Under no borrowing, D 0 is ignored. Thus, the posterior mean of jjD(T) is unbiased. Increasing the baseline hazards results in fewer right-censored patients, which decreases risk. In contrast, the pooled design offers maximal variance reduction, and thus is associated with the largest reductions in risk at D100% = 0%. However, this approach precludes learning about intra-control heterogeneity, which leads to prohibitively biased estimators with sharply, uniformly increasing risk that exceeds no borrowing for jD100%j . 2%. The adaptive design offers a compromise. For jD100%j\3:5%, it leads to estimators that dominate no borrowing for risk. Bias is attenuated for large values of jD100%j, leading to near replication of no borrowing risk for jD100%j . 10%. No borrowing dominates for intermediate intra-control effects, (À10%\D100%\ À3:5%) [ (3:5%\D100% \10%). However, adaptive borrowing leads to considerable reductions in risk and bias when compared to naive pooling over this portion of the parameter space. The hierarchical model's spike-and-slab hyperparameters can be adjusted to modulate risk tolerance in the presence of intermediate intra-control effects. In addition, the simulations suggest the estimator is relatively robust to the choice of O 1 .
Discussion
In this article, we proposed an adaptive trial design that implements a randomization procedure for allocating patients aimed at balancing total information (concurrent and historical) among the study arms by assigning more patients to receive the novel therapy in the absence of evidence for heterogeneity among the concurrent and historical controls, and yields an estimator of the novel treatment effect that obtains desirable frequentist properties. The proposed design promises to enhance efficiency in the prospective evaluation of new therapies involving controlled clinical trials that follow recent evaluations of the control therapy in the presence of little intra-control heterogeneity without risking highly biased estimation in the presence of substantial intra-control heterogeneity.
The proposed adaptive trial was considered in a 'non-sequential' setting involving a single treatment comparison at the end of the trial. That is, the design, while sequential in assessing evidence for heterogeneity among the historical and concurrent controls, did not incorporate decision rules for early stopping for efficacy or futility. Extending the proposed adaptive trial to allow for earlier stopping is an area for potential future development. Indeed, other areas for future development are many, since they include any setting where we wish to adjust trial enrollment adaptively based on an updated estimate of how much strength may be sensibly borrowed from external data sources. For instance, when historical information is also available on the new treatment, we may have two commensurability calculations, each having their own impact on the randomization ratio (11) . Alternatively, in a onearm device safety trial, we may use commensurate priors to decide when to stop accrual based on the predictive probability of a favorable end result given the current estimate of the total effective sample size. While our approach is exclusively Bayesian, Freedman and Spiegelhalter [22] have considered clinical trials that use Bayesian methods for design and frequentist methods for final analysis.
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